Metformin/rosuvastatin - BC World Pharm

Drug Profile

Metformin/rosuvastatin - BC World Pharm

Alternative Names: BCWP-C001; BCWP_C001

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator BC World Pharm
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipidaemia

Most Recent Events

  • 01 Dec 2016 BC World Pharm completes a phase I trial in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT01992211)
  • 09 Jul 2016 Phase-I clinical trials in Hyperlipidaemia (In volunteers) in South Korea (PO) prior to July 2016
  • 04 Dec 2013 BC World Pharm plans a phase I trial in healthy volunteers in South Korea (NCT01992211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top